Opening Summary
The Acting Attorney General noticed a hearing on the notice of proposed rulemaking that would transfer marijuana from Schedule I to Schedule III, with the DEA identifying interested participants for the ALJ proceeding.
What Happened
According to U.S. Drug Enforcement Administration on April 28, 2026 in Federal — DEA, The Acting Attorney General noticed a hearing on the notice of proposed rulemaking that would transfer marijuana from Schedule I to Schedule III, with the DEA identifying interested participants for the ALJ proceeding. The primary source is linked in the Source section below; readers are encouraged to review it directly for full context.
Why This Is Trending Now
The ALJ hearing is the last major federal process step before a final adult-use rescheduling decision and is drawing intense industry and investor attention.
Why Businesses Should Pay Attention
A full rescheduling outcome would extend §280E relief, banking access, and research pathways beyond medical to adult-use operators.
Practical Considerations
Businesses may want to monitor the status of the underlying rule, filing, proceeding, or announcement as it evolves. Companies may need to evaluate how this development could interact with current contracts, licenses, disclosures, and compliance programs. The issue may raise questions around vendor obligations, reporting timelines, and internal policy updates that warrant discussion with qualified counsel.
Cogent Law Perspective
We track the DEA docket in real time and help clients understand how procedural rulings and evidentiary developments affect their license strategy. The best next step is to speak with counsel about the facts specific to your organization.
Key Takeaways
- The ALJ hearing is the last major federal process step before a final adult-use rescheduling decision and is drawing intense industry and investor attention.
- A full rescheduling outcome would extend §280E relief, banking access, and research pathways beyond medical to adult-use operators.
- We track the DEA docket in real time and help clients understand how procedural rulings and evidentiary developments affect their license strategy.
- Review the primary source from U.S. Drug Enforcement Administration for the full record before making any decisions.
- Speak with Cogent Law to discuss how this development may affect your business.
Related Practice Areas
Cannabis and Hemp Law
Licensing, operations, M&A, and compliance for cannabis businesses.
Learn MoreCorporate and M&A
Formation, governance, financings, and M&A across regulated industries.
Learn MoreTalk to Cogent Law
Have questions about how this update may affect your business?
Get a Cogent Law briefing on the DEA rescheduling proceeding.
Source
U.S. Drug Enforcement Administration · April 28, 2026
Read the original sourceSource confidence: High · Verified
Legal Disclaimer
This update is provided for general informational purposes only and does not constitute legal advice. Reading this update does not create an attorney-client relationship. For advice regarding a specific matter, please contact Cogent Law.
